Lymphoma and plasma cell neoplasms
Non-Hodgkin lymphoma
Staging of Hodgkin and Non-Hodgkin lymphomas

Topic Completed: 1 February 2011

Revised: 6 February 2019

Copyright: 2001-2017,, Inc.

PubMed Search: staging hodgkin AND non-hodgkin lymphoma

Page views in 2018: 514
Page views in 2019 to date: 228
Cite this page: Sangle N. Staging of Hodgkin and Non-Hodgkin lymphomas. website. Accessed May 25th, 2019.
Definition / general
  • I: Involvement of a single lymphatic site (i.e., nodal region, Waldeyer ring, thymus or spleen)
  • IE: Localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement
  • II: Involvement of two or more lymph node regions on the same side of the diaphragm
  • IIE: Localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm; number of regions involved may be indicated by a subscript, as in II3
  • III: Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE, S); splenic involvement is designated by the letter S
  • IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s); stage IV includes any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid

National Cancer Institute Modified Staging for Intermediate and High Grade Lymphomas
  • I: Localized disease (nodal or extranodal)
  • II: Two or more nodal sites or a localized extranodal site plus draining sites plus either performance status ≤ 70, B symptoms, any mass > 10 cm, serum LDH > 500, 3 or more extranodal sites of disease
  • III: Stage II and any poor prognostic factor
Back to top